Skip to main content
CivicGate

HR 4623
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Plain Prescription Prices Act

To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.

Introduced Jul 22, 2025

Latest action (Jul 22, 2025) Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Policy area
Issues
Healthcare

Summary

  • Requires the Centers for Medicare & Medicaid Services to issue regulations within one year requiring direct-to-consumer television advertisements for prescription drugs and biological products covered by Medicare or Medicaid to include the list price for a typical 30-day regimen or course of treatment
  • Requires the list price to be based on the first day of the quarter when the advertisement airs
  • Requires the list price information to be presented as a truthful and not misleading textual statement in the advertisement
  • Directs CMS to determine the manner and format of price statements, enforcement mechanisms, and whether to extend the requirement to other forms of advertising and include additional price information

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)

4 cosponsors

Actions (2)

  1. Jul 22, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
  2. Jul 22, 2025 Introduced in House

Full text

IN THE HOUSE OF REPRESENTATIVES

July 22, 2025

Ms. Williams of Georgia (for herself, Mr. Bacon, Ms. Craig, and Mr. Steil) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Plain Prescription Prices Act”.

SEC. 2. REGULATING ADVERTISEMENTS FOR PRESCRIPTION DRUG AND BIOLOGICAL PRODUCT PRICES.

(a) In General.—Not later than one year after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Administrator of the Centers for Medicare & Medicaid Services (referred to in this section as the “Administrator”), shall promulgate regulations requiring each direct-to-consumer advertisement on television (including broadcast, cable, streaming, and satellite television) for a prescription drug or biological product for which payment is available under title XVIII or XIX of the Social Security Act to include a textual statement, which shall be truthful and not misleading, indicating the list price, as determined on the first day of the quarter during which the advertisement is being aired or otherwise broadcast, for a typical 30-day regimen or typical course of treatment (whichever is most appropriate).

(b) Determinations.—In promulgating regulations under subsection

(a), the Administrator shall determine—

(1) whether such regulations should apply with respect to additional forms of advertising;

(2) the manner and format of textual statements described in such subsection;

(3) appropriate enforcement mechanisms; and

(4) whether such textual statements should include any other price information, as appropriate. <all>

Text versions (1)

  • Introduced in House · Jul 22, 2025

Only one text version is on file, so there’s no earlier version to compare against yet.

Comments

Comments

Loading comments…